Roper Technologies Reports Strong Q1 2026 Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 25 2026
0mins
Source: Yahoo Finance
- Significant Revenue Growth: Roper Technologies reported an 11% revenue increase in Q1 2026, reaching $2.10 billion, driven by 6% organic growth and contributions from acquisitions, showcasing the company's strong market performance and ongoing expansion capabilities.
- Improved Profitability: Adjusted net earnings rose 4% to $539 million, while adjusted diluted EPS grew 8% to $5.16, reflecting the company's success in cost control and operational efficiency.
- Capital Repurchase Strategy: The company repurchased 4.3 million shares for $1.5 billion during the quarter, with the board authorizing an additional $3 billion for share buybacks, indicating a commitment to enhancing long-term free cash flow per share.
- Optimistic Outlook: Roper Technologies raised its full-year 2026 adjusted diluted EPS guidance to a range of $21.80 to $22.05, with management attributing this positive outlook to strong demand for its mission-critical solutions and accelerated delivery of AI-integrated products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ROP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ROP
Wall Street analysts forecast ROP stock price to rise
15 Analyst Rating
10 Buy
2 Hold
3 Sell
Moderate Buy
Current: 329.970
Low
419.00
Averages
558.36
High
650.00
Current: 329.970
Low
419.00
Averages
558.36
High
650.00
About ROP
Roper Technologies, Inc. is a diversified technology company. It operates businesses that design and develop vertical software and technology-enabled products for a variety of defensible niche markets. The Company operates through three segments: Application Software, Network Software and Technology Enabled Products. The Application Software segment includes Aderant, Clinisys, Data Innovations, Deltek, Frontline, IntelliTrans, PowerPlan, Procare, Strata, Transact/CBORD, and Vertafore. The Network Software segment includes ConstructConnect, DAT, Foundry, iPipeline, iTradeNetwork, Loadlink, MHA, SHP, and SoftWriters. The Technology Enabled Products segment includes CIVCO Medical Solutions, FMI, Inovonics, IPA, Neptune, Northern Digital, rf IDEAS, and Verathon. Aderant is a comprehensive management software solution for law and other professional services firms. Data Innovations is a software solution that enables the enterprise management of hospitals and independent laboratories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chartwell Law Adopts Aderant Expert Sierra to Enhance Operational Efficiency
- Cloud Management Platform: Chartwell Law's adoption of Aderant Expert Sierra, a cloud-based practice and financial management platform, positions it as a cloud-first law firm, enhancing scalability and security to support rapid nationwide growth.
- Efficiency Gains: By eliminating reliance on fragmented systems and automating workflows, Expert Sierra enables Chartwell Law to accelerate work-to-cash cycles and maximize profitability, which is expected to significantly enhance ROI for both attorneys and management.
- Real-Time Visibility: The new platform provides attorneys with real-time access to billing, timekeeping, and matter management tools, streamlining daily tasks and improving client service, while offering leadership a single source of truth for firmwide operations to facilitate faster decision-making.
- AI Investment Strategy: The adoption of Expert Sierra is part of Chartwell Law's broader investment in AI and custom development, aiming to build a modern integration and automation layer in collaboration with technology partners like Aderant, enhancing data quality and responsive reporting to create a scalable foundation for future AI-driven capabilities.
See More
DAT Freight Expands Reload Feature in Convoy Platform
- Reload Feature Expansion: DAT Freight & Analytics has expanded the reload feature in the Convoy Platform app, allowing carriers to view available freight near delivery stops before booking, optimizing transport planning and reducing empty miles to enhance profitability.
- Enhanced Decision Support: By displaying the number of reloads at the top of the load details page, carriers can better assess each opportunity, avoiding entry into weaker markets, thereby improving overall transport efficiency and profit margins.
- Positive User Feedback: Early adopter ExpedICE Logistics noted that knowing available freight in advance helps them make more informed decisions, reducing ineffective deadhead miles and ensuring profitable truck operations.
- Significant Industry Impact: DAT Freight continues to set innovation standards in the trucking and logistics industry, attracting carriers to its platform, which is expected to further drive digital transformation and efficiency improvements in the market.
See More
Nurix and Roche Form Strategic Collaboration for B-cell Therapies
- Collaboration Overview: Nurix has entered a global collaboration with Roche to develop and commercialize the oral BTK degrader bexobrutideg, receiving an upfront payment of $700 million and potential milestone payments up to $2.3 billion, highlighting the strong partnership potential in oncology and immunology.
- Clinical Development Plan: The collaboration builds on pivotal trials in chronic lymphocytic leukemia (CLL) and expands to therapeutic combination regimens across various B-cell malignancies, with plans for Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria, addressing significant unmet medical needs.
- Revenue Sharing Structure: In the U.S., Nurix and Roche will co-commercialize bexobrutideg, sharing profits and losses equally, while Nurix will receive royalties ranging from the low to high teens on sales outside the U.S., ensuring ongoing revenue for Nurix in the global market.
- Mechanism of Action Advantages: Bexobrutideg, as a highly selective BTK degrader, utilizes the body's natural protein degradation system to effectively eliminate BTK protein, overcoming resistance issues associated with existing BTK inhibitors, showcasing broad application potential in B-cell malignancies and immune-mediated diseases.
See More
Roper Technologies Reports Strong Q1 2026 Performance
- Significant Revenue Growth: Roper Technologies reported an 11% revenue increase in Q1 2026, reaching $2.10 billion, driven by 6% organic growth and contributions from acquisitions, showcasing the company's strong market performance and ongoing expansion capabilities.
- Improved Profitability: Adjusted net earnings rose 4% to $539 million, while adjusted diluted EPS grew 8% to $5.16, reflecting the company's success in cost control and operational efficiency.
- Capital Repurchase Strategy: The company repurchased 4.3 million shares for $1.5 billion during the quarter, with the board authorizing an additional $3 billion for share buybacks, indicating a commitment to enhancing long-term free cash flow per share.
- Optimistic Outlook: Roper Technologies raised its full-year 2026 adjusted diluted EPS guidance to a range of $21.80 to $22.05, with management attributing this positive outlook to strong demand for its mission-critical solutions and accelerated delivery of AI-integrated products.
See More
Roper Technologies Declares Quarterly Dividend of $0.91
- Quarterly Dividend Declaration: Roper Technologies has declared a quarterly dividend of $0.91 per share, payable on July 22 to shareholders of record as of July 8, with an ex-dividend date also set for July 8, demonstrating the company's strong cash flow and commitment to shareholder returns.
- Earnings Performance Exceeds Expectations: In Q1 2026, Roper reported a non-GAAP EPS of $5.16, beating estimates by $0.17, while revenue reached $2.1 billion, exceeding expectations by $40 million, indicating the company's robust competitive position and profitability.
- Optimistic Future Outlook: Roper projects a 2026 DEPS range of $21.80 to $22.05, reflecting management's confidence in future performance and providing investors with clear earnings guidance.
- Buyback Authorization Expansion: The company announced an expansion of its buyback authorization to $3 billion, aimed at enhancing shareholder value and market confidence by reducing the number of shares outstanding, thereby increasing EPS.
See More
Roper Technologies Declares $0.91 Dividend Per Share
- Dividend Announcement: Roper Technologies has declared a dividend of $0.91 per share, payable on July 22, 2026, to shareholders of record on July 8, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Market Position: As a constituent of the Nasdaq 100, S&P 500, and Fortune 1000, Roper Technologies holds a leading position in various defensible niche markets, enhancing its attractiveness to investors.
- Financial Stability: Known for its long-term track record of compounding cash flow and shareholder value, Roper Technologies indicates effective financial management and capital allocation strategies.
- Acquisition Strategy: The company employs a disciplined, analytical, and process-driven approach to redeploy excess capital toward high-quality acquisitions, further solidifying its leadership in technology and software sectors.
See More
Chartwell Law Adopts Aderant Expert Sierra to Enhance Operational Efficiency
- Cloud Management Platform: Chartwell Law's adoption of Aderant Expert Sierra, a cloud-based practice and financial management platform, positions it as a cloud-first law firm, enhancing scalability and security to support rapid nationwide growth.
- Efficiency Gains: By eliminating reliance on fragmented systems and automating workflows, Expert Sierra enables Chartwell Law to accelerate work-to-cash cycles and maximize profitability, which is expected to significantly enhance ROI for both attorneys and management.
- Real-Time Visibility: The new platform provides attorneys with real-time access to billing, timekeeping, and matter management tools, streamlining daily tasks and improving client service, while offering leadership a single source of truth for firmwide operations to facilitate faster decision-making.
- AI Investment Strategy: The adoption of Expert Sierra is part of Chartwell Law's broader investment in AI and custom development, aiming to build a modern integration and automation layer in collaboration with technology partners like Aderant, enhancing data quality and responsive reporting to create a scalable foundation for future AI-driven capabilities.
See More
DAT Freight Expands Reload Feature in Convoy Platform
- Reload Feature Expansion: DAT Freight & Analytics has expanded the reload feature in the Convoy Platform app, allowing carriers to view available freight near delivery stops before booking, optimizing transport planning and reducing empty miles to enhance profitability.
- Enhanced Decision Support: By displaying the number of reloads at the top of the load details page, carriers can better assess each opportunity, avoiding entry into weaker markets, thereby improving overall transport efficiency and profit margins.
- Positive User Feedback: Early adopter ExpedICE Logistics noted that knowing available freight in advance helps them make more informed decisions, reducing ineffective deadhead miles and ensuring profitable truck operations.
- Significant Industry Impact: DAT Freight continues to set innovation standards in the trucking and logistics industry, attracting carriers to its platform, which is expected to further drive digital transformation and efficiency improvements in the market.
See More
Nurix and Roche Form Strategic Collaboration for B-cell Therapies
- Collaboration Overview: Nurix has entered a global collaboration with Roche to develop and commercialize the oral BTK degrader bexobrutideg, receiving an upfront payment of $700 million and potential milestone payments up to $2.3 billion, highlighting the strong partnership potential in oncology and immunology.
- Clinical Development Plan: The collaboration builds on pivotal trials in chronic lymphocytic leukemia (CLL) and expands to therapeutic combination regimens across various B-cell malignancies, with plans for Phase 2 trials in multiple sclerosis and chronic spontaneous urticaria, addressing significant unmet medical needs.
- Revenue Sharing Structure: In the U.S., Nurix and Roche will co-commercialize bexobrutideg, sharing profits and losses equally, while Nurix will receive royalties ranging from the low to high teens on sales outside the U.S., ensuring ongoing revenue for Nurix in the global market.
- Mechanism of Action Advantages: Bexobrutideg, as a highly selective BTK degrader, utilizes the body's natural protein degradation system to effectively eliminate BTK protein, overcoming resistance issues associated with existing BTK inhibitors, showcasing broad application potential in B-cell malignancies and immune-mediated diseases.
See More
Roper Technologies Reports Strong Q1 2026 Performance
- Significant Revenue Growth: Roper Technologies reported an 11% revenue increase in Q1 2026, reaching $2.10 billion, driven by 6% organic growth and contributions from acquisitions, showcasing the company's strong market performance and ongoing expansion capabilities.
- Improved Profitability: Adjusted net earnings rose 4% to $539 million, while adjusted diluted EPS grew 8% to $5.16, reflecting the company's success in cost control and operational efficiency.
- Capital Repurchase Strategy: The company repurchased 4.3 million shares for $1.5 billion during the quarter, with the board authorizing an additional $3 billion for share buybacks, indicating a commitment to enhancing long-term free cash flow per share.
- Optimistic Outlook: Roper Technologies raised its full-year 2026 adjusted diluted EPS guidance to a range of $21.80 to $22.05, with management attributing this positive outlook to strong demand for its mission-critical solutions and accelerated delivery of AI-integrated products.
See More
Roper Technologies Declares Quarterly Dividend of $0.91
- Quarterly Dividend Declaration: Roper Technologies has declared a quarterly dividend of $0.91 per share, payable on July 22 to shareholders of record as of July 8, with an ex-dividend date also set for July 8, demonstrating the company's strong cash flow and commitment to shareholder returns.
- Earnings Performance Exceeds Expectations: In Q1 2026, Roper reported a non-GAAP EPS of $5.16, beating estimates by $0.17, while revenue reached $2.1 billion, exceeding expectations by $40 million, indicating the company's robust competitive position and profitability.
- Optimistic Future Outlook: Roper projects a 2026 DEPS range of $21.80 to $22.05, reflecting management's confidence in future performance and providing investors with clear earnings guidance.
- Buyback Authorization Expansion: The company announced an expansion of its buyback authorization to $3 billion, aimed at enhancing shareholder value and market confidence by reducing the number of shares outstanding, thereby increasing EPS.
See More
Roper Technologies Declares $0.91 Dividend Per Share
- Dividend Announcement: Roper Technologies has declared a dividend of $0.91 per share, payable on July 22, 2026, to shareholders of record on July 8, 2026, demonstrating the company's ongoing commitment to shareholder returns.
- Market Position: As a constituent of the Nasdaq 100, S&P 500, and Fortune 1000, Roper Technologies holds a leading position in various defensible niche markets, enhancing its attractiveness to investors.
- Financial Stability: Known for its long-term track record of compounding cash flow and shareholder value, Roper Technologies indicates effective financial management and capital allocation strategies.
- Acquisition Strategy: The company employs a disciplined, analytical, and process-driven approach to redeploy excess capital toward high-quality acquisitions, further solidifying its leadership in technology and software sectors.
See More
